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ABSTRACT
Numerous studies have demonstrated that dietary intervention may promote
health and help prevent Alzheimer’s disease (AD). We recently reported that bee
products of royal jelly (RJ) and enzyme-treated royal jelly (eRJ) were potent to
promote healthy aging in C. elegans. Here, we examined whether RJ/eRJ consumption
may benefit to mitigate the AD symptom in the disease model of C. elegans. Our results
showed that RJ/eRJ supplementation significantly delayed the body paralysis in AD
worms, suggesting the β-amyloid (Aβ) toxicity attenuation effects of RJ/eRJ. Genetic
analyses suggested that RJ/eRJ-mediated alleviation of Aβ toxicity in AD worms
required DAF-16, rather than HSF-1 and SKN-1, in an insulin/IGF signaling dependent
manner. Moreover, RJ/eRJ modulated the transactivity of DAF-16 and dramatically
improved the protein solubility in aged worms. Given protein solubility is a hallmark
of healthy proteostasis, our findings demonstrated that RJ/eRJ supplementation
improved proteostasis, and this promotion depended on the transactivity of DAF-16.
Collectively, the present study not only elucidated the possible anti-AD mechanism
of RJ/eRJ, but also provided evidence from a practical point of view to shed light on
the extensive correlation of proteostasis and the prevention of neurodegenerative
disorders.

INTRODUCTION

disorders [5, 6]. Thus, aggregation and accumulation
of aberrant proteins are shared common features of
many age-related neurodegenerative diseases, although
detailed molecular mechanisms of their pathogenesis
remain unclear [7, 8]. AD is considered a proteotoxicity
caused disease, which manifests obvious β-amyloid
(Aβ) aggregations and Tau proteins nucleation [9, 10]. It
is known that eukaryotic cells equipped a sophisticated
network (proteostasis network) to maintain healthy
proteostasis by eliminating aberrant proteins and
concomitant proteotoxicity [11]. However, aging will
perturb this regulatory network and decrease the protective
capacity of proteostasis [12, 13]. Thus, developing
therapeutic means to promote proteostasis network is a
promising research avenue for the treatment of AD and
other neurodegenerative disorders.
Numerous studies have shown that active
ingredients from functional foods potently promote
healthy aging [14-18], implying that dietary intervention

Alzheimer’s disease (AD) is the most observed
neurodegenerative disorder in aged populations. Given age
is the greatest risk factor for AD development, the aging
of the baby-boom generation will lead to the explosive
increase in the number of people with AD in the United
States. As neuropathological lesions gradually impair the
ability of thinking, communication, and memory [1-4], it
is a big challenge for medical professionals to take care
of AD patients. The steep cost of caring for these patients
will be another significant impact on the healthcare
system. Therefore, finding means to prevent or delay the
onset of AD is one of the most urgent commitments in
aging research.
A growing body of evidence showed that
environmental stresses and cellular lesions may cause
protein misfolding, aggregation, and amyloid formation,
which are associated with protein toxicity and various
www.impactjournals.com/oncotarget
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may be a feasible means to prevent or delay the onset
of AD. Royal jelly (RJ) and enzyme-treated RJ (eRJ)
are consumed as functional foods due to their beneficial
effects, such as antimicrobial, anti-inflammation, immunemodulation, and anti-oxidation [19, 20]. RJ is secreted by
worker bees and used for developing and maintaining
the queen bees [21]. eRJ is produced by digestion of
RJ with a hydrolytic enzyme to decrease the allergenic
properties [22]. We recently reported that supplementation
of both RJ and eRJ significantly promoted lifespan and
stress resistance in C. elegans [18]. Given that certain
nutraceuticals with prolongevity effects may promote
proteostasis and attenuate proteotoxicity [17], it is
intriguing to test whether RJ/eRJ is able to influence the
proteostasis network to prevent or delay AD.
C. elegans that model age-related disorders of
neurodegeneration offers tremendous opportunities to
study the molecular mechanisms of these diseases and to
determine the effectiveness of therapeutic strategies [2327]. To date, studies from worm models demonstrated
that reduction of insulin/IGF signaling pathway (IIS)
protected organisms from proteotoxicity [28-34].
Remarkably, these findings were reported to be conserved
in mammalian animals [35-37]. CL2006 is a transgenic
C. elegans in which human Aβ1-42 is constitutively
expressed in the muscle cells. The subsequent aggregation
of Aβ polypeptides leads to progressive body paralysis
[30, 38], providing a unique platform to study AD and
proteotoxicity. Here, we supplemented CL2006 worms
with RJ/eRJ and investigated whether RJ/eRJ may help
alleviate Aβ toxicity. Our results showed that RJ/eRJ
dramatically delayed the progression of Aβ toxicityinduced paralysis and significantly reduced Aβ species
in AD worms. Further genetic analyses showed that this
anti-AD effect required DAF-16, rather than HSF-1 and
SKN-1, in an IIS dependent manner. In addition, we found
that RJ/eRJ supplementation substantially improved the
protein solubility in aged worms. Considering that protein
solubility associates with healthy proteostasis, these results
demonstrated that RJ/eRJ acts through IIS and DAF-16 to
promote proteostasis and mitigate proteotoxicity. Taken
together, our findings not only revealed the possible
molecular mechanism of RJ/eRJ-mediated protection
against Aβ toxicity, but also highlighted the regulation of
DAF-16 on the proteostasis network from a practical point
of view.

employed and the body paralysis was used as the readout
to assess the degree of Aβ toxicity. As we previously
reported that 2mg/ml RJ and 1mg/ml eRJ significantly
prolonged C. elegans lifespan, the same concentrations
of RJ and eRJ were adopted in this study [18]. In brief,
synchronous CL2006 L4/young adult worms were
treated with or without RJ/eRJ (2mg/mL and 1mg/
mL, respectively) at 20°C and paralyses were measured
every day until all AD worms were paralyzed. Our data
indicated that RJ/eRJ supplementation dramatically
delayed the progression of CL2006 worms’ paralysis when
compared with the non-supplemented controls (Figure 1).
Considering that body paralysis is mainly triggered by Aβ
toxicity, our finding suggested that RJ/eRJ could potently
alleviate Aβ toxicity in AD worms.

RJ/eRJ supplementation reduces the amount of
Aβ species in AD worms
It is reported that many nutraceuticals delayed the
development of AD by mitigating Aβ toxicity through
decreasing Aβ species [17, 39-41]. We questioned whether
RJ/eRJ was able to alleviate Aβ toxicity through a similar
mechanism. To this end, synchronized CL2006 young
adult worms were treated with or without RJ/eRJ (2mg/
mL and 1mg/mL, respectively) for 10 days at 20°C.
Afterward, Western blotting was performed to assay
for the total amount of Aβ species in these 10-day aged
worms. Data were analyzed using NIH ImageJ software,
and our findings showed that the total amount Aβ species
in AD worms treated with RJ and eRJ were 13.61% and
21.90% less than that in the control AD worms, which
were statistically significant (p < 0.05, Figure 2). Given
that the amount of Aβ species contribute to Aβ toxicity,

RESULTS
Figure 1: Supplementation of both RJ and eRJ mitigates
Aβ toxicity in C. elegans. The CL2006 worms treated with RJ

RJ/eRJ supplementation delays the progression of
paralysis in AD worms

(dashed line) and eRJ (dotted line) showed delayed progression
of body paralysis as compared to the control worms (solid line).
Each paralysis assay was conducted in triplicates and repeated
at least three times with similar results. “% paralysis” indicates
the average paralysis among the multi-replicates and error bars
represent the standard deviation.

To determine whether RJ/eRJ possesses the
beneficial effects to AD treatment, CL2006 worms were
www.impactjournals.com/oncotarget
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our results suggested that RJ/eRJ attenuated Aβ toxicity, at
least in partial, by reducing the level of Aβ species.

suggested that IIS and DAF-16 were essential in RJ/eRJmediated protective effect against Aβ toxicity.
As DAF-16 is a versatile transcription factor, it is
very likely that the RJ/eRJ-mediated protection against
Aβ toxicity may depend on the transactivity of DAF16. To examine this speculation, synchronized CL2006
L4/young adult worms were treated with or without RJ/
eRJ for 6 days, and some representative target genes
of DAF-16 were selected to measure their expression
levels, individually. Our results showed that sod-3, mtl1, Y71H2AR.2, hsp-16.2, and hsp-12.6 were significantly
upregulated in CL2006 worms treated with RJ/eRJ when
compared with non-supplemented controls (Figure 3D).
These results not only indicated that RJ/eRJ protected
against Aβ toxicity through modulating the transactivities
of DAF-16, but also further confirmed our genetic
analysis that daf-16 was required by RJ/eRJ to delay the
progression of paralysis in AD worms.

IIS and DAF-16 are required in RJ/eRJ-mediated
protection against Aβ toxicity
It was reported that the reduction of IIS prevented
neurodegeneration in mammals and worms by modulating
the transactivities of its downstream transcription factors
[42]. Our previous studies showed that IIS and DAF16 played an essential role in RJ/eRJ-mediated lifespan
extension and stress resistance [18]. Considering the
potential link between prolongevity and anti-AD function,
we wondered whether IIS and DAF-16 also played an
imperative role in RJ/eRJ-mediated protection against
Aβ toxicity. To address this, the paralysis progression of
CL2006 worms supplemented with RJ/eRJ was monitored
when the gene expression of daf-2, age-1, and daf-16 were
individually knocked down via RNA interference (RNAi).
In detail, synchronous AD worms were collected from
RJ/eRJ containing NGM plates seeded with particular
aforementioned RNAi or a paired control (empty vector,
EV) bacteria. When worms developed into L4/young
adult, paralysis assays were performed every day until
all AD worms were paralyzed. In our assays, RJ/eRJ
supplementation still dramatically delayed the progression
of paralysis in CL2006 worms treated with paired control
RNAi. In contrast, RNAi of daf-2, age-1, and daf-16 in
CL2006 worms completely abolished RJ/eRJ-mediated
beneficial effects on delaying the progression of paralysis
(Figure 3A, 3B, and 3C). These findings together

HSF-1 and SKN-1 are dispensable in RJ/eRJmediated protection against Aβ toxicity
In addition to DAF-16, SKN-1 and HSF-1 are two
other important transcription factors downstream of IIS,
and also play an important role in alleviating Aβ toxicity
in C. elegans [42]. Given that RJ/eRJ relied on IIS to
alleviate Aβ toxicity, we were curious whether SKN-1
and HSF-1 may also contribute to this RJ/eRJ-mediated
anti-AD effect, just like DAF-16. To this end, CL2006
worms supplemented with RJ/eRJ were fed with RNAi
bacteria of skn-1 and hsf-1, respectively. CL2006 worms
fed with control RNAi (paired empty vector) bacteria
served as controls. Intriguingly, our results showed that
supplementation of RJ/eRJ still delayed the progression
of paralysis in CL2006 worms fed with skn-1 or hsf-1
RNAi bacteria (Figure 4A and 4B). These results indicated
that SKN-1 and HSF-1 might be dispensable in RJ/eRJmediated protection against Aβ toxicity.

RJ/eRJ supplementation improved proteostasis in
aged C. elegans
Proteostasis machinery alleviates proteotoxicity
to maintain the integrity of the proteome [43-47]. Given
that RJ/eRJ consumption mitigated Aβ toxicity in AD
worms, we speculated whether RJ/eRJ may modulate
the proteostasis network to present anti-AD effect in
aged populations. Thus, we tested the overall solubility
of proteins in aged worms since protein solubility is a
primary hallmark of healthy proteostasis [45, 48, 49].
Specifically, synchronized worms of wild type N2 and
CL2006 treated with or without RJ/eRJ were harvested
to extract total proteins. After sonication and high speed
centrifugation, soluble fractions were isolated from the
total proteins. SDS-PAGE and ImageJ were utilized

Figure 2: Supplementation of both RJ and eRJ reduces
the amount of total Aβ species. Western blot analysis was

conducted using 10-day old CL2006 worms. Aβ species are
quantified by using ImageJ software. A significant reduction of
intensity is observed in the samples from worms that had been
treated with RJ and eRJ. The graph shows the mean intensity of
Aβ species and is the result of three independent experiments.
p value was calculated using Student’s t-test. *, p < 0.05 when
compared to controls.
www.impactjournals.com/oncotarget
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to determine whether RJ/eRJ affected the solubility of
proteins in aged C. elegans. Relative to non-supplemented
controls, RJ/eRJ supplementation increased 26.95% (RJ)
and 26.87% (eRJ) of soluble proteins in N2 worms (Figure
5A). Similarly, RJ/eRJ also displayed an average increase
of 27.13% (RJ) and 21.27% (eRJ) of soluble proteins
in CL2006 worms as compared to non-supplemented
controls (Figure 5B). Together, these results suggested
that RJ/eRJ profoundly improved proteostasis in aged C.
elegans.
Given the fact that DAF-16 was essential in RJ/
eRJ-mediated lifespan extension, stress resistance, and
protection against Aβ toxicity, we speculated that DAF-

16 may also participate in RJ/eRJ-mediated promotion of
proteostasis and protein solubility. To test this speculation,
synchronized daf-16 (mgDf50) mutant worms were treated
with or without RJ/eRJ for 10 days. Thereafter, worms
were collected for total protein extraction. Sonication
and centrifugation were utilized to remove the insoluble
proteins, and the amount of soluble proteins was analyzed
by SDS-PAGE and ImageJ software. Not surprisingly,
RJ/eRJ-mediated improvement of protein solubility was
abolished in the daf-16 deletion mutant, suggesting the
essential role of daf-16 in RJ/eRJ-mediated promotion of
proteostasis (Figure 5C).

Figure 3: RJ/eRJ requires IIS and DAF-16 to protect against Aβ toxicity in CL2006 worms. A. RJ/eRJ supplementation

cannot further postpone the progression of body paralysis in CL2006 worms with reduced IIS by daf-2 RNAi. B. RJ/eRJ supplementation
cannot further delay the progression of paralysis in CL2006 worms with reduced IIS by age-1 RNAi. C. Reducing DAF-16 by daf-16 RNAi
significantly abolished the beneficial effects of RJ/eRJ delaying the progression of body paralysis in AD worms. Each paralysis assay was
repeated at least three independent times with similar results. “% paralysis” indicates the average paralysis among the multi-replicates and
error bars represent the standard deviation. D.The transcript levels of aip-1, F10D7.5, mtl-1, sod-3, Y71H2AR.2, ZK218.8, hsp-16.2, hsp12.6, and T05G5.10 were measured using qRT-PCR in CL2006 worms supplemented with RJ/eRJ (2mg/ml and 1mg/ml, respectively).
The data from three independent experiments were pooled to calculate the mean RNA level normalized to the internal control act-1. The
standard errors of the mean (SEM) are shown. *, p < 0.05 when compared to non-treated controls.
www.impactjournals.com/oncotarget
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DISCUSSION

It was reported that reduction of the IIS pathway
prevents neurodegeneration in worms and mammals,
and this preventive effect relies on the transactivities of
three important transcription factors (daf-16, skn-1, and
hsf-1) [42]. Given that IIS played an essential role in RJ/
eRJ-mediated protection against Aβ toxicity (Figure 3),
we thus wondered whether RJ/eRJ may preferentially
influence the function of these downstream transcription
factors contributing to the reduction of proteotoxicity. To
address this concern, RNA interference was utilized to
respectively knock down the gene expression of daf-16,
hsf-1, and skn-1, respectively. Our genetic epistasis results
showed that RNAi of either skn-1 or hsf-1 did not abolish
RJ/eRJ-mediated progression delay of body paralysis
(Figure 4A and 4B), while RNAi of daf-16 in CL2006
AD worms completely abolished the progression delay of
paralysis, relative to controls (Figure 3D). These findings
indicated that RJ/eRJ’s protection against Aβ toxicity
in C. elegans is mainly dependent on DAF-16. Given
that inefficiency of proteostasis machinery results in the
accumulation of aggregates [43], such as Aβ aggregates,
we reasoned that RJ/eRJ supplementation protected AD
worms against Aβ toxicity by improving the regulation of
proteostasis. Considering that DAF-16 plays a pivotal role
in proteostasis network [28], our results suggested that RJ/
eRJ supplementation selectively modulate the transactivity
of DAF-16 to improve proteostasis in AD worms.
Ben-Zvi et al. demonstrated that collapse of
proteostasis leads to impaired protein solubility and
increased cytotoxicity [48]. Reis-Rodrigues and colleagues
further claimed that accumulation of insoluble proteins
with diverse biological functions may be a general
feature of normal aging and late-onset neurodegenerative

It has emerged that some anti-aging nutraceuticals
could delay the development of neurodegenerative
disorders. For instance, cranberry protected C. elegans
from thermal stress and slowed down the development
of AD [16, 50]. Antioxidant resveratrol not only had
prolongevity effect but also delayed the development of
Alzheimer’s disease and Parkinson’s disease [51, 52]. Our
previous studies reported that RJ/eRJ supplementation
not only extended C. elegans lifespan, but also increased
their stress resistant capacity. This implied that RJ/eRJ
consumption could lead to healthy aging in multicellular
organisms. Hence, our present studies attempted to
further investigate the potential beneficial effect of RJ/
eRJ on AD treatment and its underlying molecular
mechanisms. Strikingly, our results showed that RJ/eRJ
supplementation delayed the progression of paralysis in
AD worms. Further genetic analyses suggested that RJ/
eRJ requires daf-16, rather than skn-1 and hsf-1, to protect
against Aβ toxicity. Mechanistic studies demonstrated that
RJ/eRJ modulates the transactivities of DAF-16 through
IIS cascade. Moreover, RJ/eRJ consumption resulted in
the reduction of Aβ species in AD worms and greatly
increased the solubility of proteins in aged worms [45, 48,
49]. Intriguingly, the improvement of protein solubility
conferred by RJ/eRJ supplementation also required the
function of DAF-16. Considering the correlation of protein
solubility and proteostasis, and the imperative role of
DAF-16 in regulating proteostasis, our findings suggested
that RJ/eRJ may alleviate Aβ toxicity by promoting the
function of proteostasis machinery in C. elegans through
IIS and DAF-16.

Figure 4: skn-1 and hsf-1 are dispensable in RJ/eRJ-mediated protection against Aβ toxicity. A. RJ/eRJ supplementation

can still delay the progression of Aβ toxicity-induced paralysis in AD worms with SKN-1level reduced by skn-1 RNAi. B. RJ/eRJ
supplementation can still delay the progression of body paralysis in AD worms with HSF-1 level reduced by hsf-1 RNAi. Each paralysis
assay was repeated at least three independent times with similar results. “% paralysis” indicates the average paralysis among the multireplicates and error bars represent the standard deviation.
www.impactjournals.com/oncotarget
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Figure 5: RJ/eRJ improves proteostasis in aged C. elegans in a DAF-16 dependent manner. A. RJ/eRJ treatment increases

protein solubility in 10-day old N2 worms. B. RJ/eRJ supplementation increases protein solubility in 10-day old CL2006 AD worms. C.
RJ/eRJ treatment cannot increase protein solubility in 10-day old daf-16 (mgDf50) mutant worms. Soluble proteins on the SDS-PAGE gel
are quantified by using ImageJ software. Data are expressed as mean intensity from three independent experiments. The standard errors of
the mean (SEM) are shown. p value was calculated using Student’s t-test. *, p < 0.05 when compared to controls.
www.impactjournals.com/oncotarget
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diseases [49]. Collectively, previous findings highlighted
that a healthy proteostasis is associated with good protein
solubility and attenuated proteotoxicity. Interestingly,
our results showed that RJ/eRJ significantly increased
protein solubility in both aged wild type worms and
aged AD worms, which suggested that RJ/eRJ possessed
the capability to help maintain a healthy proteostasis
in C. elegans. Given that RJ/eRJ requires DAF-16
to protect against Aβ toxicity, we speculated that
DAF-16 is also essential in RJ/eRJ-mediated healthy
proteostasis maintenance. In support of our speculation,
our further protein solubility assay showed that RJ/eRJ
supplementation barely altered the protein solubility in
aged daf-16 deletion mutants. Taken together, our results
attributed RJ/eRJ-mediated reduction of Aβ toxicity to
DAF-16 and the improved proteostasis.
Given that most of, if not all, cellular functions
depend on gene expression, the dependence of DAF-16
in RJ/eRJ-mediated proteostasis improvement proposed
that RJ/eRJ may modulate the target gene expression of
DAF-16 to influence proteostasis network. To address this,
we selected several DAF-16 target genes and performed
qRT-PCR to measure their expression in AD worms
treated with or without RJ/eRJ. Intriguingly, RJ/eRJ
supplementation increased the expression levels of sod-3,
mtl-1, hsp-12.6, hsp-16.2, and Y71H2AR.2 (Figure 3D).
sod-3 and mtl-1 gene products play an important role in
detoxification and homeostasis of ROS and heavy metal,
respectively [53, 54]. hsp-12.6 and hsp-16.2 encode two
essential chaperone proteins to prevent the aggregation of
misfolded and unfolded proteins in response to proteotoxic
stressors [55, 56]. Impressively, overexpression of HSP16.2 could suppress the Aβ toxicity in AD worms.
Y71H2AR.2 encodes a protease, which may facilitate
protein degradation through proteolysis [57]. Considering
that stress response, molecular chaperone, and regulation
of protein degradation are major components of the
proteostasis network [11], our results implicated that RJ/
eRJ may alleviate Aβ toxicity by modulating proteostasis
network through DFA-16. It is also worth noticing that
expression of other selected genes, such as ZK218.8,
T05G5.10, aip-1, and F10D7.5, was barely influenced
by RJ/eRJ supplementation (Figure 3D), although they
are probably related to proteostasis network. ZK218.8
and T05G5.10 encode translation initiation factors and
function in protein synthesis [57, 58], while aip-1 and
F10D7.5 gene products function to facilitate toxic protein
degradation under stress [59]. It was reported that RJ/
eRJ-mediated prolongevity relied on fine-tune of DAF-16
transactivity through interplay with multiple proteins [18].
The expression preference of DAF-16 targets conferred
by RJ/eRJ in AD worms actually suggested that RJ/eRJ
may also fine-tune the transactivity of DAF-16, and in
turn specifically up-regulate the expression of certain
proteins associated with proteostasis network. It will be of
great interest to decipher the RJ/eRJ-mediated fine-tune
www.impactjournals.com/oncotarget

regulation on DAF-16 in AD worms. Of course, more
experiments are needed to this end.
A growing body of evidence suggests that bioactive
substances in natural foods interplay with cellular proteins,
nuclear acids, and lipids by the chemical modification or
physical interaction, to influence human health [60]. It
is conceivable that the bioactive ingredients in RJ may
function through the similar modes of action to ameliorate
Aβ toxicity in animals. Given that RJ is a unique mixture
rich of proteins, carbohydrates, lipids, minerals, and
vitamins [61], in order to boost the therapeutic effects of
RJ, it is critical to determine its functional components
corresponding to the reduction of proteotoxicity in cells.
Indeed, our finding that RJ/eRJ depends on DAF-16 to
improve the function of proteostasis provides a simple and
clear readout to determine these active components from
RJ/eRJ.
Overall, our finding revealed the molecular
mechanisms of RJ/eRJ-mediated alleviation of Aβ toxicity
in C. elegans, and explicitly underscored the correlation
of proteostasis maintenance and proteotoxicity reduction
in cells. As both IIS/DAF-16(FOXOs) and proteostasis
network are highly conserved in species ranging from C.
elegans to human, the potential function of RJ/eRJ in AD
treatment might also be beneficial to humans.

MATERIALS AND METHODS
Strains and growth conditions
All strains were maintained at 16 °C on nematode
growth medium (NGM) seeded with Escherichia coli
OP50 feeding strain. Strains used in this study were as
follows: N2 Bristol (wild type), CL2006 (AD worm), and
daf-16 (mgDf50). All the strains were obtained from the
Caenorhabditis Genetics Center (CGC), University of
Minnesota.

Preparation of RJ and eRJ
The powder of RJ and eRJ were provided by
Yamada Apiculture Center, Inc., Okayama, Japan. To
prepare RJ and eRJ supplemented food, appropriate
amount of RJ or eRJ in powder form were dissolved in
sterile distilled water and suspended into the liquid NGM
(2mg/mL RJ and 1mg/mL eRJ) one day before the assay
[18].

RNA interference
RNA interference (RNAi) clones were grown
overnight at 37°C on Luria Broth plate in the presence
of tetracycline (12.5 µg/ml) and carbenicillin (25 µg/
54189
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Soluble protein extraction

ml). Bacterial colonies were inoculated and grown for
8-12 hours, then induced with 2mM isopropyl β-D-1thiogalactopyranoside (IPTG) for 4 hours at 37°C. Tenfold concentrated RNAi bacteria were seeded onto RNAi
plates containing 25 µg/ml carbenicillin. The RNAi
constructs targeting daf-2, age-1, daf-16, hsf-1, and skn1 were obtained from the C. elegans ORFeome RNAi
library v1.1.

The soluble protein extraction was performed
as described previously with alterations [17, 49].
Synchronous populations of eggs were prepared by
alkaline hypochlorite treatment of gravid adults grown
at 16°C. Eggs were allowed to hatch and develop by
transferring to OP50-seeded NGM plates containing
RJ (2mg/mL) or eRJ (1mg/mL) at 20°C. Eggs hatched
and developed on OP50-seeded NGM plates without
RJ/eRJ served as controls. Both worms treated with or
without RJ/eRJ were collected 10 days after L4 stage.
Three separate replicates of each sample (about 200mg
[wet weight] of worms) were collected. Total protein
extracts were produced in phosphate-buffered saline by
sonication on ice, and then the total protein concentration
was determined by conducting a bicinchoninic acid assay.
Next, the normalized protein samples were spun for 10
minutes at 14,000g to remove the insoluble fraction. The
same volume of supernatants (soluble fraction) was loaded
and analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. Mean intensities of protein bands
were analyzed using ImageJ software (National Institute
of Health).

Worm paralysis assays
The assays using strain CL2006 were carried out
as described by Cohen and colleagues [28]. Synchronous
populations of CL2006 worms were prepared on NGM
plates by allowing 10-15 hermaphrodites lay eggs
overnight at 16°C, and the parents were removed the
next day. The eggs were allowed to hatch, and 30 L4/
young adult worms per plate were used for each assay at
20°C. All paralysis plots were done in triplicates, and a
minimum of three independent trials were performed per
condition. Nematodes were scored as paralyzed if they
exhibited “halos” of cleared bacteria around their heads
(indicative of insufficient body movement to access food)
or failed to undergo full body wave propagation upon
the nose prodding. Worms were checked every day until
all worms were paralyzed. The data were pooled, and
the percentage of paralyzed worms was calculated and
analyzed using Student’s t-test. p < 0.05 was accepted as
statistically significant.

Gene expression analysis by quantitative real-time
PCR
CL2006 worms were synchronized by allowing
10-15 hermaphrodites to lay eggs for 6 hours on OP50
seeded NGM plates at 16°C. The eggs were allowed to
hatch and develop. The L4 /young adult worms were
transferred to RJ/eRJ (2 and 1mg/mL respectively) NGM
plates (containing 50 µg/mL FUDR to prevent the growth
of progeny) to maintain for 6 days. CL2006 worms on
regular NGM (containing FUDR) plates without RJ/eRJ
served as controls. Worms at the 6-day old stage were
collected with M9 buffer into a 50-100-µl pellet. RNA
was prepared using RNAzol® RT reagent (Molecular
Research Center) and stored at −80°C. Complementary
DNA was prepared by using Invitrogen SuperscriptTM
first-strand synthesis system for RT-PCR (Invitrogen).
Real-time PCR was performed using using SsoFastTM
EvaGreen® Supermix (Bio-Rad) and the CFX96TM realtime PCR detection system according to the manufacturer
suggested protocol (Bio-Rad). The quantitative real-time
PCR (qRT-PCR) conditions were as follows: 95°C for 3
minutes, followed by 40 cycles of 10 seconds at 95°C,
and 30 seconds at 60°C. act-1 was used as an internal
control to normalize the expression level of target
transcripts. Relative fold-changes for transcripts were
calculated using the comparative CT(2−ΔΔCT) method (43).
Each qRT-PCR experiment was repeated three times
using independent RNA/cDNA preparations. The data
were pooled and analyzed using student’s t-test, and a

Western blotting of Aβ species
Rabbit polyclonal Aβ1-42 primary antibodies were
from Abcam (ab39377). For Western blot analysis,
CL2006 worms were synchronized by allowing 10-15
hermaphrodites to lay eggs overnight on OP50 seeded
NGM plates at 16°C. The parents were removed, and
eggs were allowed to hatch and develop to the L4 stage.
Subsequently, worms were transferred to RJ (2mg/mL) /
eRJ (1mg/mL) containing NGM plates and continued to
grow at 20°C. CL2006 worms on regular NGM plates
without RJ/eRJ served as control. After 10 days of growth,
worms were transferred to micro-centrifuge tubes and
washed with S-basal followed by protein immobilization
on polyvinylidenefluoride (Bio-Rad) membrane.
Polyvinylidenefluoride membrane was incubated with
primary antibodies (1:1,000) diluted in 5% nonfat dry
milk and then with secondary, HRP-conjugated goat antirabbit antibodies (Genscript, A00098; diluted 1:10,000).
ACTIN was used as loading control, and the anti-ACTIN
antibodies (MAB1501) were from EMD Millipore.
Detection was undertaken with standard ECL protocol.
Mean intensity of Aβ signals was analyzed using ImageJ
software (National Institute of Health).
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p value < 0.05 was accepted as statistically significant.
The qRT-PCR primers for hsp-12.6 are as follows:
5′-ATGATGAGCGTTCCAGTGATGGCTGACG-3′
(F)
and5′-TTAATGCATTTTTCTTGCTTCAATG
TGAAGAATTCC-3′ (R). Primers for hsp-16.2 are
as follows: 5′-TTGCCATCAATCT CAACGTC-3′
(F)
and
5′-CTTTCTTTGGCGCTTCAATC-3′
(R).
Primers
for
sod-3
are
as
follows:
5′-CCAACCAGCGCTG-AAATT CAATGG-3′ (F)
and
5′-GGAACCGAAGTCGCGCTTAATAGT-3′
(R).
Primers
for
mtl-1
are
as
follows:
5′-ATGGCTTGCAAGTGTGACTG-3′
(F)
and
5′-CACATTTGTCTCCGCACTTG-3′ (R). Primers for aip1 are as follows: 5’- GAGCGGGATCACAGTTGTGAG-3’
(F) and 5’- GATGTGATTGAATCCGTCCAG-3’
(R). Primers for F10D7.5 are as follows: 5’GCACTAGAGGACCATTACAGTT-3’
(F)
and
5’CGTTCTCGTCAATCTCGATAGG-3’
(R). Primers for ZK218.8 are as follows: 5’TGCTACTGGCTGTGTGTTAG-3’
(F)
and
5’CAATAGTTCCGGCATTCACATAAT-3’
(R). Primers for T05G5.10 are as follows: 5’GGAGACTTGGGAAACACTATCC-3’
(F)
and
5’TGTATCCGAGAATAGCCTCCT-3’
(R). Primers for Y71H2AR.2 are as follows:
5’GAGTTGTGGCAGAGGGTAATG-3’
(F)
and
5’GGATGGGTTGTAGATTCCGATTT-3’
(R). Primers for act-1are as follows: 5′CCAGGAATTGCTGATCGTATGCAGAA-3′ (F) and
5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R).
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